Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.
J Infect Dis
; 227(2): 221-225, 2023 01 11.
Article
em En
| MEDLINE
| ID: mdl-35978486
ABSTRACT
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 messenger RNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that 3 antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several postbooster breakthrough cases caused by the Omicron variant.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas
/
COVID-19
Limite:
Humans
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Japão